NO20082023L - Pyrrolotriazin kinaseinhibitorer - Google Patents

Pyrrolotriazin kinaseinhibitorer

Info

Publication number
NO20082023L
NO20082023L NO20082023A NO20082023A NO20082023L NO 20082023 L NO20082023 L NO 20082023L NO 20082023 A NO20082023 A NO 20082023A NO 20082023 A NO20082023 A NO 20082023A NO 20082023 L NO20082023 L NO 20082023L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
formula
pyrrolotriazine kinase
pyrrolotriazine
compounds
Prior art date
Application number
NO20082023A
Other languages
English (en)
Norwegian (no)
Inventor
Ping Chen
Yufen Zhao
Brian Fink
Soong-Hoon Kim
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20082023L publication Critical patent/NO20082023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20082023A 2005-11-18 2008-04-29 Pyrrolotriazin kinaseinhibitorer NO20082023L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73826905P 2005-11-18 2005-11-18
US11/560,378 US7514435B2 (en) 2005-11-18 2006-11-16 Pyrrolotriazine kinase inhibitors
PCT/US2006/044756 WO2007061882A2 (fr) 2005-11-18 2006-11-17 Pyrrolotriazine en tant qu’inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
NO20082023L true NO20082023L (no) 2008-08-05

Family

ID=38051768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082023A NO20082023L (no) 2005-11-18 2008-04-29 Pyrrolotriazin kinaseinhibitorer

Country Status (9)

Country Link
US (1) US7514435B2 (fr)
EP (1) EP1948664B1 (fr)
JP (1) JP5095626B2 (fr)
KR (1) KR101392678B1 (fr)
CN (1) CN101365701B (fr)
AT (1) ATE512151T1 (fr)
AU (1) AU2006318682B2 (fr)
NO (1) NO20082023L (fr)
WO (1) WO2007061882A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8143393B2 (en) 2005-12-02 2012-03-27 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8124759B2 (en) * 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
BRPI0812839A2 (pt) * 2007-07-03 2014-12-09 Sanofi Aventis Processo para o acoplamento catalisado por paládio de alcinas terminais com tosilatos de heteroarila e benzenossulfonatos de heteroarila
WO2009042543A1 (fr) 2007-09-25 2009-04-02 Bayer Healthcare Llc Dérivés de pyrrolotriazine utiles pour le traitement d'un cancer par inhibition d'aurora kinase
EP2206707B1 (fr) 2007-10-24 2014-07-23 Astellas Pharma Inc. Composé à base d'azolecarboxamide ou son sel
WO2010042684A1 (fr) * 2008-10-08 2010-04-15 Bristol-Myers Squibb Company Inhibiteurs de la pyrrolotriazine kinase
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
EP2424368B1 (fr) * 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Composés de pyrrolotriazine
US8791257B2 (en) * 2010-03-31 2014-07-29 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
EA023775B1 (ru) * 2011-07-01 2016-07-29 Байер Интеллектуэль Проперти Гмбх Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US9598416B2 (en) 2011-12-15 2017-03-21 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
HUE038512T2 (hu) 2012-11-13 2018-10-29 Array Biopharma Inc N-pirrolidinil-, N'-pirazolil-karbamid, tiokarbamid, guanidin és cianoguanidin vegyületek mint TrkA kináz inhibitorok
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HUE031557T2 (en) 2012-11-13 2017-07-28 Array Biopharma Inc Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
PL3154959T3 (pl) 2014-05-15 2019-12-31 Array Biopharma, Inc. 1-((3S,4R)-4-(3-Fluorofenylo)-1-(2-metoksyetylo)pirolidyn-3-ylo)-3-(4-metylo-3- (2- metylopirymidyn-5-ylo)-1-fenylo-1H-pirazol-5-ilo)-mocznik jako inhibitor kinazy TrkA
CN104151276A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 一种盐酸决奈达隆代谢杂质的制备方法
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
EP3209664B1 (fr) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Composés aminés hétéroaryliques bicycliques utilisés comme inhibiteurs de pi3k
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
CN112225723B (zh) * 2020-12-16 2021-03-30 北京华氏开元医药科技有限公司 一种吲哚类衍生物、制备方法及应用
WO2022235054A1 (fr) * 2021-05-03 2022-11-10 주식회사 제이비케이랩 Composition pharmaceutique pour prévenir, soulager ou traiter le cancer, contenant du 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phénol en tant que principe actif

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227554A (zh) 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
MXPA01011832A (es) 1999-05-21 2002-06-21 Squibb Bristol Myers Co Inhibidores de cinasas, de pirrolotriazina.
US6787545B1 (en) * 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
EP1503996B1 (fr) * 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Composes aryle cetone pyrrolo-triazine utiles comme inhibiteurs de kinase
TW200407143A (en) * 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6951859B2 (en) * 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
EP1945222B1 (fr) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Derives pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines comme inhibiteurs de la igf-1r kinase pour le traitement des cancers et d'autres maladies hyperproliferatives

Also Published As

Publication number Publication date
AU2006318682B2 (en) 2012-04-05
KR20080079262A (ko) 2008-08-29
EP1948664B1 (fr) 2011-06-08
WO2007061882A3 (fr) 2007-08-16
AU2006318682A1 (en) 2007-05-31
CN101365701A (zh) 2009-02-11
US20070149534A1 (en) 2007-06-28
ATE512151T1 (de) 2011-06-15
WO2007061882A2 (fr) 2007-05-31
US7514435B2 (en) 2009-04-07
KR101392678B1 (ko) 2014-05-07
JP5095626B2 (ja) 2012-12-12
EP1948664A2 (fr) 2008-07-30
JP2009515995A (ja) 2009-04-16
CN101365701B (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
NO20082023L (no) Pyrrolotriazin kinaseinhibitorer
NO20091374L (no) Pyrrolotriazin kinase inhibitorer
FR21C1031I1 (fr)
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20062188L (no) Pyrazolderivater som inhibitorer av reseptor tyrosin kinaser
NO20081160L (no) Benzimidazoltiofen forbindelser
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20081454L (no) Met-kinaseinhibitorer
NO20070323L (no) Organiske forbindelser
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
NO20081844L (no) Terapeutiske forbindelser
EA200801199A1 (ru) Ингибиторы киназы
NO20083246L (no) Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
NO20080079L (no) AMPA-reseptorpotensiatorer
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
NO20082412L (no) Kinaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application